Background: Lysosome associated protein transmembrane 4 beta (LAPTM4B) was identified first as a novel gene overexpressed in human hepatocellular carcinoma. LAPTM4B*1 and LAPTM4B*2 are two alleles of the gene; they are differentiated at 5 0 UTR in the first exon. Allele *1 contains only one copy of a 19-bp sequence in the 5 0 UTR. However, allele *2 contains another identical 19-bp sequence following the first one tightly. In this case-control study, we aimed to identify the relationship between LAPTM4B gene polymorphism and the susceptibility of primary liver cancer.
introduction
Primary liver cancer is a malignant disease that seriously threatens the health and safety of human beings. It is the fifth most common cancer and the third most common cause of cancer-related death worldwide [1] . According to World Health Organization report (2006) , >600 000 patients died from primary liver cancer annually, and this figure is rising each year [2, 3] . Incidences vary in different countries, with the highest rate occurring in circum-Pacific of Asia and South of Sahara [4] . Chronic hepatitis B virus (HBV) infection is the most important environmental factor, and correlation between aflatoxin B1and the development of liver cancers was found in previous studies [5] . Since the primary liver cancer is a rapidly fatal disease, early diagnosis is essential for better prognosis [6] .
LAPTM4B was identified as a novel gene overexpressed in human hepatocellular carcinoma (HCC). It was first cloned using fluorescence differential display, rapid amplification of cDNA ends and RT-PCR. According to BLAST program analysis, the LAPTM4B gene is mapped on to chromosome 8q22.1, which spans ∼50 kb and composed of seven exons separated by six introns [7] . Two alleles of the LAPTM4B gene exist, named LAPTM4B*1 and LAPTM4B*2 (GenBank accession numbers AY219177 and AY219176, respectively), and therefore three genotypes exist. They are differentiated at the 5 0 UTR in the first exon. Allele *1 contains only one copy of a 19-bp sequence in the 5 0 UTR. However, allele *2 contains another identical 19-bp sequence following the first one tightly ( Figure 1 ).
Previous study has indicated that LAPTM4B was associated with differentiation of HCC and may be involved in the development of tumor [7] . In this case-control study, we compare the LAPTM4B gene polymorphism among different groups of patients in order to determine the effects of genetic variations on the susceptibility of primary liver cancer.
materials and methods

sample collection case group
Blood samples were collected from 303 primary liver cancer patients (248 male and 55 female, mean age 57.0 ± 11. 
control group
Five hundred and fifteen age-matched (304 male and 211 female, mean age 57.9 ± 14.2 years) control subjects were recruited from patients attending physical examination in the clinical laboratory of Beijing Cancer Hospital (168 controls were recruited between October 2009 and April 2010 and 347 controls were quoted from the data of Liu et al. [8] ). The controls were screened to ensure that they were free of cancer.
All patients signed written informed consent.
DNA preparation
Fasting venous blood (2 ml) was drawn from the median cubital vein of each patient in the morning, collected in EDTA anticoagulation tube and stored at −20°C. Genomic DNA extraction was carried out using the phenol/chloroform method. Briefly, the blood was directly thawed in 20°C water bath and then 1 ml blood was transferred to 10 ml centrifuge tube. After the addition of phosphate-buffered saline, the tube was centrifuged at 3500 g for 15 min, discarding the supernatant. Centrifugation was again carried out until the precipitation turns white. Centrifuged products were then resuspended in 0.75 ml lysis buffer, followed by the addition of 7.5 μl proteinase K (20 mg/ml) and digestion in 37°C water bath for 3 h. The digested solution was extracted three times using phenol/chloroform method. Purified DNA was stored at −20°C until further testing.
gene polymorphism analyses of LAPTM4B results Figure 2 shows the allelic sequencing chromatography of LAPTM4B. Two alleles of LAPTM4B generated three kinds of genotypes, i.e. *1/1, *1/2 and *2/2. Primers were designed to sit on both sides of the 19-bp sequence in the first exon; Chinese genomic DNA was used as template to amplify gene LAPTM4B by PCR. According to the analysis on gene polymorphism of LAPTM4B with agrose gel electrophoresis, we identified three genotypes, which are shown in Figure 3 . The 204-bp band codes for the homozygous genotype *1/1, 223-bp band for the homozygous genotype *2/2 while the heterozygous genotype *1/2 has both 204-bp and 223-bp bands. For the positive control, human β-actin, 318-bp band codes. In this study, 303 primary liver cancer cases (248 male and 55 female, mean age 57.0 ± 11.7 years) and 515 healthy controls (304 male and 211 female, mean age 57.9 ± 14.2 years) were investigated. Table 1 shows the characteristics of case and control groups. According to the median age of groups, we divided the ages into two groups while there was no significant statistical difference in age between the case and control subjects (P = 0.482). The incidence of male in primary liver cancer cases (81.8%) was higher than in control group (59.0% male), resulting in different distribution in gender between case and control subjects (P < 0.05).
Genotypes distribution of case and control groups were consistent with Hardy-Weinberg equilibrium (P = 0.999 and 0.588), indicating that the sampling was a good representative of the population. The frequency of genotypes and alleles of LAPTM4B in cases and controls are as summarized in Table 2 . We found higher proportions of genotype *1/2 and *2/2 in primary liver cancer patients (51.5% and 13.2%, respectively) compared with healthy population (39.8% and 7.4%, respectively). Crosstabs test indicates statistical significance in distribution of genotype *1/2 and *2/2 between the two patient groups (P < 0.05). Odds ratio analysis showed that LAPTM4B*1/2 and *2/2 were associated with a significant increased risk of primary liver cancer compared with LAPTM4B*1/1 (OR = 1.898, 95% CI = 1.387-2.598 and OR = 2.483, 95% CI = 1.480-4.168, respectively). It is also found that the frequency of allele *2 was higher in cases (38.9%) than in controls (27.3%). Patients carrying LAPTM4B*2 allele indicated 1.652-fold higher risk of developing primary liver cancer than those carrying LAPTM4B*1 (P < 0.05, OR = 1.652, 95% CI = 1.327-2.058). The analysis above was adjusted by gender. Our findings suggested that LAPTM4B*2 may be a risk factor for the development of primary liver cancer cases, while LAPTM4B*1 appears to be the protective one.
Furthermore, correlations of LAPTM4B genotypes to clinicopathologicals (age, gender, infection of HBV, cirrhosis, α- 
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fetoprotein, pathological type and classification of TNM) had also been investigated (Table 3 ). There was no association between LAPTM4B genotypes and clinicopathological variables studied. discussion LAPTM4B was originally identified as a gene overexpressed in human HCC, and it has inverse correlation with HCC differentiation. According to literatures, 87.3% (48/55 cases) of HCC tissues showed LAPTM4B's overexpression when compared with paired noncancerous liver and normal liver tissues [7] . Higher level of expression was also found in poorly differentiated HCC tissues than in well-differentiated ones [9] . Additionally, LAPTM4B was highly up-regulated in majority of solid carcinomas, such as lung and colon cancers, by means of Affymetrix GenChip hybridization(Affymetrix Company). Northern blot results also revealed the overexpression of LAPTM4B in the majority of carcinomas of uterus, breast and ovary [10] . LAPTM4B expressions were also high in human HCC cell lines and some other cancer cell lines [11, 12] . Evidences suggest that the overexpression of LAPTM4B may induce out of control cell proliferation and enhancement of tissue invasion [13] .
On the other hand, other studies revealed that LAPTM4B gene encodes for two different proteins with different molecular weights (35 and 24 kD), which were translated from different ATGs in the open reading frame (nt 157 and nt 430). By the use of western blot analysis, using the LAPTM4B-N28-37-pAb or LAPTM4B-EC2-pAb, previous studies showed that expression of LAPTM4B-35 proteins were highly up-regulated in HCC with poor differentiation as the expression of LAPTM4B messenger RNA (mRNA) [14, 15] . Recently, a number of studies demonstrated that LAPTM4B-35 may be an important risk factor for tumor recurrence and independent molecular marker of prognosis in HCC, ovarian carcinoma, extrahepatic cholangiocarcinoma, gallbladder and endometrial carcinoma [16] [17] [18] [19] . Furthermore, study also showed that LAPTM4B promotes the growth and metastasis of HCC [20] ; LAPTM4B overexpression is a new predictor of epithelial ovarian carcinoma metastasis [21] . Therefore, LAPTM4B is thought to play an important role in progression of some tumors, especially HCC.
Our study aimed to investigate the impact of gene polymorphism of LAPTM4B on primary liver cancer. We observed that allele LAPTM4B*2 had increased risk (OR = 1.652) of developing primary liver cancer than LAPTM4B*1 allele. Therefore, allele *2 may be a latent risk factor, causing accumulation of genotype LAPTM4B *2/2 in liver cancer group. It appears that the expression of LAPTM4B gene was out of control in the presence of carcinogens in the environment. In comparison with allele *2, allele *1 appears to be more protective against primary liver cancer. Previous researches reported that LAPTM4B*2 allele was associated with increased susceptibility of lung cancer [22] , lymphoma [23] , gastric cancer [8] , colon cancer [24] and cervical cancer [25] . The risk of suffering these cancers were increased to 1.720-, 1.610-, 1.710-, 1.523-and 1.490-fold in individuals possessing allele *2 in comparison with *1, respectively, although no statistical significance was found for rectal or esophageal cancer [24] . Comprehensive analysis of above results showed the association between LAPTM4B gene polymorphism and increased susceptibility of cancers in cancers derived from single-layer cuboidal and columnar epithelia [15] . Although there were several general characteristics in the occurrence and development of different tumors, such as activation of oncogenes and inactivation of tumor suppressor genes, tumor specificity was showed in the molecular genetics between different cancers. Therefore, study on LAPTM4B gene in various tumors is an important step in improving our understanding of cancers. The relationship between LAPTM4B gene polymorphism and susceptibility of primary liver cancer could be explained by the following aspects. Preliminary studies cloned LAPTM4B gene promoter and compared its activities in BEL7402 and HLE cells, while transcription factor regulated by LAPTM4B may be different in these cell lines. Southern blot analysis did not show amplification of LAPTM4B in liver cancers [7] . Therefore, it is presumed that the reason for LAPTM4B overexpression in liver cancer could be due to uncontrolled transcriptional regulation rather than gene amplification. Furthermore, there are multiple potential combining sites of transcription factor in the upstream of LAPTM4B promoter, such as c-Ets-1, LYF-1, E2F, c-JUN and c-Myb, some of which are proto-oncogene itself. The activation of these oncogenes may up-regulate LAPTM4B.
In addition, Xiao Jing et al. [26] analyzed LAPTM4B expression in esophageal cancer and methylation sites on the first exon and promoter region of LAPTM4B. This study found three CpG sites within the LAPTM4B promoter region in one particular normal tissue sample at 418-, 416-and 398-bp upstreams of the transcription initiation site. We concluded that the degree of methylation at multiple CpG sites within the LAPTM4B core promoter region significantly affects its mRNA expression level in esophageal cancer tissues; however, more studies should be carried out to prove this presumption.
For comparison of differences between LAPTM4B*1 and *2, we identified the unique region of 19-bp sequence at 5 0 UTR in the first exon. In fact, there were regulatory regions and sequence in the first exon of many genes [27] , which can combine some nucleoproteins or transcription factors together. These elements can regulate gene transcription even the specific expression in different cells or tissues. A study showed the transcription activity of allele *2 to be 19% lower than that of allele *1 [7] . Therefore, the 19 bp at 5 0 UTR on LAPTM4B may be a potential regulatory region, which can regulate the transcription of LAPTM4B.
Additionally, the structures of protein coded by two alleles may differ and may determine various activities and functions. The diversity may affect cell metabolism to carcinogen and other physiological processes and therefore, may result in different susceptibility to primary liver cancer. As shown in Figure 4 , there are several termination codons in the 5 0 UTR of LAPTM4B *1, which ORF can only encode for a protein of 317 amino acids. On the other hand, due to presence of double 19-bp fragments, the corresponding stop codon of LAPTM4B *2 is eliminated for displacement, which induces the addition of 53 amino acids in N-terminal, and as a result, the protein encoded by allele *2 consisted of 370 amino acids. A previous Data were calculated using unconditional logistic regression.
study found that the 91 amino acids of N-terminal are important for the function of LAPTM4B, and it is the vital molecular functional domain [7] . Also, the N-terminal protein sequence of LAPTM4B might be involved in signal transduction, thus enhancing cell proliferation or survival [28] . To sum up, primary liver cancer is a challenging malignancy of global importance with high rate of mortality. Chronic infection with HBV and hepatitis C viruses (HCV) as well as cigarette smoking are established risk factors of HCC. HBV is a major risk factor for the development of primary liver cancer. China accounts for 55% of cases of liver cancer worldwide due to the high prevalence of HBV infection [29] . In our study, we analyzed the correlations of LAPTM4B genotypes to HBV, while we cannot collect the informations about HCV and cigarette smoking in controls because the physical examination of control subjects do not contain these items. So that is a pity, we will continue to study it in the following trials. However, infection with hepatitis B alone does not explain the development of primary liver cancer, and therefore, it is important to find other risks factors associating liver cancers. Our study shows that LAPTM4B*2 is an important risk factor associated with susceptibility to primary liver cancer and also a useful marker to improve treatment and prevention in future.
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